Skip to content

Evaluation of the systemic bioavailability of gentamicin released from Herafill® Beads G and Garamycin® Schwamm in patients after hip-cup arthroplasty in aseptic revision of hip endoprothesis - A comparative, randomized monocentric study

Evaluation of the systemic bioavailability of gentamicin released from Herafill® Beads G and Garamycin® Schwamm in patients after hip-cup arthroplasty in aseptic revision of hip endoprothesis - A comparative, randomized monocentric study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
DRKS
Registry ID
DRKS00023902
Enrollment
30
Registered
2021-01-05
Start date
2010-10-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ASEPTICREVISIONOFHIPENDOPROTHESIS

Interventions

Group 1: Herafill® Beads G Group 2: Garamycin® Schwamm

Sponsors

Heraeus Medical GmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 75 years 2. Patients with an implanted hip prosthesis which needs surgical revision of aseptic nature. 3. Informed consent given in written form

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Participation in another clinical trial at same time or within the preceding 3 months 2. Any history of hypersensitivity to the active and inactive ingredients of Herafill® Beads G or of Garamycin® Schwamm, or hypersensitivity to any ingredient of the artificial hip cup 3. Concomitant systemic (oral or parenteral) administration of the active ingredient of both medical devices. 4. Congenital dislocation of the hip 5. Active infection of the hip 6. Neoplasms 7. Active rheumatoid arthritis 8. Any concomitant disease which precludes surgical revision of hip endoprosthesis 9. Patients with renal impairments determined by at least one of the following laboratory parameters outside of the normal range: - serum creatinine - serum urea 10. Inner ear damage 11. Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequences of the study 12. Unreliability or lack of cooperation 13. Lack of a possibility to attend the examinations required by the clinical investigation plan

Design outcomes

Primary

MeasureTime frame
To determine and compare the pharmacokinetics of gentamicin from Herafill® Beads G and Garamycin® Schwamm by measuring gentamicin concentrations in blood serum, urine and wound secretion.

Secondary

MeasureTime frame
To assess wound healing and safety of the medical devices under investigation.

Countries

Czechia

Contacts

Public ContactDavid Jahoda

1st Orthopaedic Clinic in Motol Teaching Hospital, 1st Medical Faculty, Charles University in Prague

david.jahoda@fnmotol.cz+420 224 433 901

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026